10-Q: Definitive Healthcare Q3: Revenue Declines Amid Macro Headwinds

Definitive Healthcare Corp. reported a 4% revenue decline in Q3 2025 and a 5% decline for the nine months, attributing the downturn to macroeconomic pressures and sales execution challenges, despite a reduced net loss.

Summary

• Revenue for the three months ended September 30, 2025, decreased by $2.7 million (4%) to $60.0 million compared to $62.7 million in the same period of 2024.
• Revenue for the nine months ended September 30, 2025, decreased by $9.9 million (5%) to $179.9 million compared to $189.9 million in the same period of 2024.
• Net loss for Q3 2025 was $(17.8) million, a significant improvement from $(187.8) million in Q3 2024, primarily due to a lower goodwill impairment charge in the current period.
• Net loss for the nine months ended September 30, 2025, was $(182.2) million, an improvement from $(506.7) million in the same period of 2024, driven by a lower goodwill impairment charge ($176.5 million in 2025 vs. $591.8 million in 2024).
• The company's total customer count decreased to approximately 2,400 as of September 30, 2025, from 2,570 a year prior, with Enterprise Customers decreasing by 10 to 520.
• Operating cash flow increased slightly to $51.1 million for the nine months ended September 30, 2025, from $50.1 million in the prior year.
• The company repaid $75.6 million of its term loan and repurchased $49.5 million of Class A Common Stock during the nine months ended September 30, 2025.
• A $176.5 million non-cash goodwill impairment charge was recorded in Q1 2025 due to declines in market capitalization.

Sentiment

Score: 3

Explanation: The company faces significant headwinds, including declining revenue, customer churn, and a negative outlook for 2025 revenue and gross margin. While net loss improved due to lower impairment charges, and debt was reduced, the core business performance metrics are deteriorating, indicating substantial challenges.

Positives

• Net loss significantly reduced for both the three and nine months ended September 30, 2025, compared to the prior year, largely due to lower goodwill impairment charges.
• Operating cash flow increased slightly to $51.1 million for the nine months ended September 30, 2025.
• Successfully repaid $75.6 million of the term loan and amended the credit agreement, extending maturity to January 16, 2030.
• Executed a stock repurchase program, buying back 13.9 million shares for $49.5 million during the nine months ended September 30, 2025.
• One-time credits from renegotiations on existing data contracts and the exit of a major data contract contributed to a decrease in hosting fees and data subscription costs.

Negatives

• Revenue declined by 4% in Q3 2025 and 5% for the nine months ended September 30, 2025, compared to the prior year.
• Customer count decreased from approximately 2,570 to 2,400 year-over-year, including a reduction of 10 Enterprise Customers.
• Sales execution challenges and lower than historical renewal rates observed throughout 2025.
• Gross profit decreased by $3.0 million in Q3 2025 and $13.5 million for the nine months ended September 30, 2025.
• Total assets decreased from $1,089.4 million to $755.5 million, and total equity decreased from $607.2 million to $389.7 million.
• Goodwill impairment charge of $176.5 million in Q1 2025 indicates a significant reduction in the fair value of the reporting unit.
• TRA liability increased by approximately $7.6 million in Q3 2025 due to tax law updates (OBBBA).

Risks

• Dependence on third parties for data, information, and services.
• Increased accessibility to free or relatively inexpensive information sources.
• Ability to maintain high annual renewal rates.
• Ability to compete in the highly competitive industry and potential adverse effects of this competition.
• Ability to maintain revenues if products and services do not achieve and maintain broad market acceptance, or if unable to keep pace with or adapt to rapidly changing technology, evolving industry standards, macroeconomic market conditions, and changing regulatory requirements.
• Changes in government policy positions, including trade policy, spending priorities, or reductions in government programs, government spending, or research funding.
• Loss of, or inability to attract and retain, key personnel.
• Effectiveness of business plans.
• Ability to derive fully the anticipated benefits from organic growth, existing or future acquisitions, joint ventures, investments, or dispositions.
• Exposure to risk from having operations and employees in other countries, including potentially adverse tax consequences.
• Strength of brand and reputation.
• Level of indebtedness, which could adversely affect business, financial condition, and results of operations.
• Ability to obtain, protect, defend, or enforce intellectual property rights.
• Ability to leverage artificial intelligence technologies (AI) in products and services.
• Significant disruption in or unauthorized access to or breaches of computer systems or those of third parties, including cybersecurity or cyberattacks.
• Use of open source software in products and services.
• Ability to comply with applicable data protection and privacy laws.
• Risk for future goodwill impairments if market capitalization experiences a continued decline or macroeconomic conditions worsen.
• Changes in the healthcare claims data market, including how data providers are reviewing pricing, data availability, and use terms, which may negatively impact data acquisition prices.

Future Outlook

The company expects revenue to decline in 2025 compared with 2024 due to ongoing macroeconomic challenges, sales execution issues, and pressures on renewals. Gross profit margin for 2025 is also anticipated to decrease due to the expansion of data sources and expected revenue declines, combined with a largely fixed cost structure. Management believes that cash flow from operations, availability under the 2021 Credit Agreement, and available cash and cash equivalents and short-term investments will be sufficient to meet liquidity needs for at least the next twelve months and in the long term.

Management Comments

• Our current and prospective customers and their business spendings are impacted by difficult macroeconomic conditions to varying degrees, resulting in lengthening deal cycles for new and existing customers, more stringent approval processes, and deferred purchasing decisions.
• We are experiencing heightened customer churn, particularly pronounced for smaller customers and in the Life Sciences market.
• Changes in the healthcare claims data market since early 2024, including how data providers are reviewing pricing, data availability, and use terms, may negatively impact the prices at which we acquire such data.
• We are working to mitigate potential risk through renegotiation of select existing agreements and the addition of new data sources.
• We expect our revenue to decline in 2025 compared with 2024.
• We believe that our cash flow from operations, availability under the 2021 Credit Agreement and available cash and cash equivalents and short-term investments will be sufficient to meet our liquidity needs for at least the next twelve months and in the long term.

Industry Context

Definitive Healthcare operates in the healthcare commercial intelligence sector, providing SaaS solutions to Life Sciences, Provider, and Diversified markets. The industry is currently facing significant macroeconomic headwinds, which are impacting customer spending, leading to longer deal cycles, deferred purchasing decisions, and heightened customer churn, particularly affecting smaller customers and the Life Sciences market. Additionally, the healthcare claims data market is experiencing disruption, affecting data pricing, availability, and use terms, which could increase the company's data acquisition costs and impact its competitive positioning.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various legal proceedings, claims, and governmental inspections, audits, or investigations that arise in the ordinary course of business.
• Management believes the ultimate resolution of these matters would not be expected to have a material adverse effect on the company's financial position, results of operations, or cash flows.

Related Party Transactions

• Recorded $0.3 million in revenue from related parties during the three months ended September 30, 2025, and $0.6 million during the nine months ended September 30, 2025.
• Paid $0.3 million to related parties during the three months ended September 30, 2025, and $0.7 million during the nine months ended September 30, 2025.
• Receivables for related party revenue transactions amounted to $0.1 million at September 30, 2025.
• Payables to related parties amounted to $0.1 million at September 30, 2025.

Stakeholder Impact

• Shareholders: Negative impact from declining revenue, customer churn, and goodwill impairment, potentially affecting share price. The share repurchase program may offer some support.
• Employees: Workforce reduction (approximately 150 people) from the 2024 Restructuring Plan and executive transitions indicate ongoing organizational changes.
• Customers: Lengthening deal cycles, more stringent approval processes, deferred purchasing decisions, and heightened churn suggest challenges in customer acquisition and retention.
• Creditors: Debt repayment and compliance with credit agreement covenants are positive, but overall financial performance decline could be a concern.
• Suppliers: Changes in the healthcare claims data market may lead to renegotiations or changes in data acquisition terms, potentially impacting data suppliers.

Next Steps

• Continue to monitor for potential goodwill impairment indicators.
• Work to mitigate risks from changes in the healthcare claims data market through renegotiation of existing agreements and adding new data sources.
• Evaluate strategic acquisitions and investments that further expand the platform.
• Invest significantly in engineering and research and development efforts to enhance capabilities and functionality and facilitate the expansion of the platform to new use cases and customers.

Key Dates

Recommendation

While the company has demonstrated some financial discipline by reducing its net loss (albeit largely due to lower impairment charges), decreasing debt, and executing share repurchases, the core business performance is concerning. Significant revenue declines, customer churn, and explicit management guidance for continued revenue and gross margin pressure in 2025 indicate substantial headwinds. The macroeconomic environment and sales execution challenges are impacting growth. Investors should hold to observe if the company's mitigation strategies for data costs and sales disruptions can reverse these negative trends, but new investment is not warranted given the current outlook and operational challenges.

Keywords

Definitive Healthcare, DH, 10-Q, Q3 2025, financial results, healthcare intelligence, SaaS, revenue decline, net loss, goodwill impairment, macroeconomic conditions, customer churn, debt repayment, stock repurchase, executive changes